Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
18 Julio 2024 - 6:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop a functional cure for people with chronic
hepatitis B virus (cHBV) infection, today announced that it has
scheduled its second quarter 2024 financial results and corporate
update for Thursday, August 1, 2024. The schedule for the press
release and conference call/webcast are as follows:
• |
Q2 2024 Press Release: |
Thursday, August 1, 2024 at 7:30 a.m. ET |
• |
Q2 2024 Conference Call/Webcast: |
Thursday, August 1, 2024 at
8:45 a.m. ET |
|
|
|
To dial-in for the conference call by phone,
please register using the following link: Registration Link. A live
webcast of the conference call can be accessed through the
Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to identify and develop novel therapeutics with
distinct mechanisms of action, which can be combined to provide a
functional cure for patients with chronic hepatitis B virus (cHBV).
We believe the key to success in developing a functional cure
involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran
has generated meaningful clinical data demonstrating an impact on
both surface antigen reduction and reawakening of the HBV-specific
immune response. Imdusiran is currently in three Phase 2a
combination clinical trials. AB-101 is currently being evaluated in
a Phase 1a/1b clinical trial. For more information, visit
www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor
RelationsPhone: 215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024